Medical and Scientific: Latitude offers payment plans for cancer test

15 Mar 2021 - Medical and Scientific

Specialised Therapeutics Australia (STA), has signed a new deal with IPO hopeful Latitude Financial Group, which will provide interest-free payment plans for up to two years for a genomic test for breast cancer that costs $5000. The multi-gene test, known as the Oncotype DX Breast Cancer Assay, predicts a patient’s likely benefit from chemotherapy and the overall risk of breast cancer recurrence. It is able to determine whether an early breast cancer patient needs chemo, or whether they can be safely treated with hormone therapy alone. Without this test, many patients might go through chemo unnecessarily.

Australian Financial Review; 15/03/2021; Page 17​